Elizaveta V. Benevolenskaya

Elizaveta V. Benevolenskaya

Auto-generated profile, based on publicly available information

Elizaveta V. Benevolenskaya

Department of Biochemistry and Molecular Genetics (M/C 669), University of Illinois, College of Medicine, Chicago, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAlexandre Ferro Aissa
Alexandre Ferro Aissa
AIAbul Islam
Abul Islam
MAMajd Ariss
Majd Ariss
CGCammille C. Go
Cammille C. Go
ARAlexandra E. Rader
Alexandra E. Rader
EBElizaveta V. Benevolenskaya
Elizaveta V. Benevolenskaya
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However, the duration of clinical response is often limited, and patients ultimately develop drug resistance. Here, we use single-cell RNA sequencing to demonstrate the existence of multiple cancer cell subpopulations within cell lines, xenograft tumors and patient tumors. These subpopulations exhibit epigenetic changes and differential therapeutic sensitivity. Recurrently overrepresented ontologies in genes that are differentially expressed between drug tolerant cell populations and drug sensitive cells include epithelial-to-mesenchymal transition, epithelium development, vesicle mediated transport, drug metabolism and cholesterol homeostasis. We show analysis of identified markers using the LINCS database to predict and functionally validate small molecules that target selected drug tolerant cell populations. In combination with EGFR inhibitors, crizotinib inhibits the emergence of a defined subset of EGFR inhibitor-tolerant clones. In this study, we describe the spectrum of changes associated with drug tolerance and inhibition of specific tolerant cell subpopulations with combination agents.

25 July 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WLWenchu Lin
Wenchu Lin
JCJian Cao
Jian Cao
JLJiayun Liu
Jiayun Liu
MBMichael L. Beshiri
Michael L. Beshiri
YFYuko Fujiwara
Yuko Fujiwara
Qin YanQin Yan
Qin Yan
Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation ofRbp2decreases tumor formation and prolongs survival inRb1+/−mice andMen1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy.

9 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMenglin Liu
Menglin Liu
LZLianghui Zhang
Lianghui Zhang
GMGlenn Marsboom
Glenn Marsboom
AJAnkit Jambusaria
Ankit Jambusaria
SXShiqin Xiong
Shiqin Xiong
AMAsrar B. Malik
Asrar B. Malik
Repair of the endothelial cell barrier after inflammatory injury is essential for tissue fluid homeostasis and normalizing leukocyte transmigration. However, the mechanisms of endothelial regeneration remain poorly understood. Here we show that the endothelial and hematopoietic developmental transcription factor Sox17 promotes endothelial regeneration in the endotoxemia model of endothelial injury. Genetic lineage tracing studies demonstrate that the native endothelium itself serves as the primary source of endothelial cells repopulating the vessel wall following injury. We identify Sox17 as a key regulator of endothelial cell regeneration using endothelial-specific deletion and overexpression of Sox17. Endotoxemia upregulates Hypoxia inducible factor 1α, which in turn transcriptionally activates Sox17 expression. We observe that Sox17 increases endothelial cell proliferation via upregulation of Cyclin E1. Furthermore, endothelial-specific upregulation of Sox17 in vivo enhances lung endothelial regeneration. We conclude that endotoxemia adaptively activates Sox17 expression to mediate Cyclin E1-dependent endothelial cell regeneration and restore vascular homeostasis.

1 August 2008 in Molecular Cell
Verified
Journal Article
Closed access
NLNuria Lopez-Bigas
Nuria Lopez-Bigas
TKTomasz A. Kisiel
Tomasz A. Kisiel
DDDannielle C. DeWaal
Dannielle C. DeWaal
KHKatie B. Holmes
Katie B. Holmes
TVTom L. Volkert
Tom L. Volkert
EBElizaveta V. Benevolenskaya
Elizaveta V. Benevolenskaya

1 August 2007 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
EBElizaveta V. Benevolenskaya
Elizaveta V. Benevolenskaya
Lysine histone methylation is one of the most robust epigenetic marks and is essential for the regulation of multiple cellular processes. The methylation of Lys4 of histone H3 seems to be of particular significance. It is associated with active regions of the genome, and in Drosophila it is catalyzed by trithorax-group proteins that have become paradigms of developmental regulators at the level of chromatin. Like other histone methylation events, H3K4 methylation was considered irreversible until the identification of a large number of histone demethylases indicated that demethylation events play an important role in histone modification dynamics. However, the described demethylases had no strictly assigned biological functions and the identity of the histone demethylases that would contribute to the epigenetic changes specifying certain biological processes was unknown. Recently, several groups presented evidence that a family of 4 JmjC domain proteins results in the global changes of histone demethylation, and in elegant studies using model organisms, they demonstrated the importance of this family of histone demethylases in cell fate determination. All 4 proteins possess the demethylase activity specific to H3K4 and belong to the poorly described JARID1 protein family.

9 October 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MBMichael L. Beshiri
Michael L. Beshiri
KHKatherine B. Holmes
Katherine B. Holmes
WRWilliam F. Richter
William F. Richter
SHSamuel Hess
Samuel Hess
AIAbul B. M. M. K. Islam
Abul B. M. M. K. Islam
EBElizaveta V. Benevolenskaya
Elizaveta V. Benevolenskaya
Epigenetic regulation underlies the robust changes in gene expression that occur during development. How precisely epigenetic enzymes contribute to development and differentiation processes is largely unclear. Here we show that one of the enzymes that removes the activating epigenetic mark of trimethylated lysine 4 on histone H3, lysine (K)-specific demethylase 5A (KDM5A), reinforces the effects of the retinoblastoma (RB) family of transcriptional repressors on differentiation. Global location analysis showed that KDM5A cooccupies a substantial portion of target genes with the E2F4 transcription factor. During ES cell differentiation, knockout of KDM5A resulted in derepression of multiple genomic loci that are targets of KDM5A, denoting a direct regulatory function. In terminally differentiated cells, common KDM5A and E2F4 gene targets were bound by the pRB-related protein p130, a DREAM complex component. KDM5A was recruited to the transcription start site regions independently of E2F4; however, it cooperated with E2F4 to promote a state of deepened repression at cell cycle genes during differentiation. These findings reveal a critical role of H3K4 demethylation by KDM5A in the transcriptional silencing of genes that are suppressed by RB family members in differentiated cells.